tradingkey.logo

Precision BioSciences Announces Phase 1 Safety And Efficacy For Cohort 1, Lowest Dose Level In Eliminate-B, A First-In-Human Trial Of Pbgene-Hbv For Chronic Hepatitis B

ReutersAug 6, 2025 1:44 PM

- Precision BioSciences Inc DTIL.O:

  • PRECISION BIOSCIENCES ANNOUNCES PHASE 1 SAFETY AND EFFICACY FOR COHORT 1, LOWEST DOSE LEVEL IN ELIMINATE-B, A FIRST-IN-HUMAN TRIAL OF PBGENE-HBV FOR CHRONIC HEPATITIS B

  • PRECISION BIOSCIENCES INC - COHORT 1 ESTABLISHED SAFE AND WELL-TOLERATED PROFILE

  • PRECISION BIOSCIENCES INC - EXTENDED CASH RUNWAY TO SECOND HALF OF 2027

  • PRECISION BIOSCIENCES INC - PBGENE-HBV SHOWED 47-69% HBSAG REDUCTION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI